December 19, 2025
Nxera Pharma to Regain Full Rights to GPR52 Agonist Program for Schizophrenia
Tokyo, Japan and Cambridge, UK, 19 December 2025 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) today…
Pharmaceuticals, Biotechnology and Life Sciences
Tokyo, Japan and Cambridge, UK, 19 December 2025 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) today…
San Diego, CA, Dec. 17, 2025 (GLOBE NEWSWIRE) — Sapu BioScience today announced the publication of a new peer-reviewed study…
HONG KONG, Dec. 17, 2025 (GLOBE NEWSWIRE) — Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ: HKPD) (“HKPD” or the…
Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel)Decision Reconfirms Allogene’s Expanded Sub-License Covering EU and UK Rights with…
– Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio’s collaboration with Moderna – – Generation Bio’s…
NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology…
MISSISSAUGA, Ontario, Dec. 15, 2025 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce…
Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., Dec. 15, 2025 (GLOBE…
AUSTIN, TX and DURHAM, NC, Dec. 15, 2025 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK),…
Abivax Presents Third Quarter 2025 Financial Results Cash and cash equivalents of EUR 589.7 (as of September 30, 2025) with…